Clinical trials

#Animal models #Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Immunology / Virology & Vaccines #Regulatory #RNA

Insect-based technology for human vaccines

06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More

#News

#Business #Clinical specialities #Clinical trials #High Content Screening #Immunology #Immunology / Virology & Vaccines #RNA

Agreement for research grade bioreagents for SARS-CoV-2 vaccine

GeoVax Labs, a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced on April 30 that Beijing- and Philadelphia-based Sino Biological, will be its exclusive supplier of SARS-CoV-2 (Covid-19) bioreagent research products. Under the terms of the agreement, Sino Biological will provide… Read More

#Covid-19 #News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Precision medicine #RNA

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate

Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content

#Animal models #Biologics / Biotechnology #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

ADCs and solid tumours – The payload revolution that drives therapeutic opportunities in unmet need

ADCs and solid tumours - The payload revolution that drives therapeutic opportunities in unmet need By Dr Jenny Thirlway Volume 21 Issue 2 - Spring 2020 The fight against cancer is ongoing. Despite progress in many indications, mortality rates for some of the most difficult to treat solid tumour types… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 - Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. While antimicrobial resistance (AMR) does… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

How sharing compound solubility data can advance drug discovery

By Andrii Lozoniuk Volume 21 Issue 2 - Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Preclinical #RNA #System biology #Systems biology #Therapeutics

Drug development 2.0 – The partnership model in practice

Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Harnessing the modified proteome for increased diagnostic power

Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Microbiome #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Patent Law #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

2030 Life Sciences and Health in the Digital Age (Part 2)

By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genomics #High Content Screening #High throughput screening #Lead discovery #Oncology #Regulatory #Screening #Sequencing #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #In Silico Biology #Lead discovery #Lead optimisation #RNA #System biology #Systems biology #Target validation #Toxicology

How Artificial Intelligence is Transforming Drug Design

How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting… Read More

#Archive

Bacteriophage
#AI / data analytics / healthtech / informatics #Animal models #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Oncology #Preclinical #Stem cells #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To capitalise on the microbiome’s potential to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Microbiome #Oncology #Pharmokinetics #Preclinical #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Microbiology #Nanomedicine / nanotechnology #Organic chemistry #Pathology #Precision medicine #Preclinical #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

2030 Life Sciences and Health in the Digital Age (Part 1)

2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to look ahead, to… Read More

#Archive